MIFEPRISTONE (mifepristone) by Teva is progestational hormone receptor antagonists [moa]. First approved in 2020.
Drug data last refreshed 19h ago
Progestational Hormone Receptor Antagonists
Progestin Antagonist
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST)
Mifepristone Dynamic Testing for Diagnosis for Central Adrenal Insufficiency
Crossover Drug-Drug Interaction Study to Determine Effects of Cytochrome P450 3A on Exposure to Mifepristone and Its Metabolites
Mifepristone Drug-Drug Interaction Study With CYP3A Inhibitor
Worked on MIFEPRISTONE at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.